
Enumeral Biomedical Corporation Profile last edited on: 12/7/2015
CAGE: 676S1
UEI: CCCVXC8UBAB3
Business Identifier: Nanotechnology-enabled process for therapeutic discovery, immune profiling and personalized medicine Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 10
County: New York
Congr. District: 10
County: New York
Public Profile
Originally doing business grounded in a license of technology from Arrowhead Research based in nanoparticle-based drug candidates, Enumeral Biomedical Corp. is focused on discovering and developing antibody immunotherapies that help the immune system fight cancer and other diseases. In August, 2014 merger wasannounced between Enumeral Biomedical Corp. and a subsidiary of Enumeral Biomedical Holdings, Inc., formerly known as Cerulean Group, Inc. Coinciding with the merger, Enumeral closed on a private placement financing and an achieved IPO with shares trading under the symbol ENUM.The firm uses its microengraving (nanotechnology-enabled) process to address opportunities in immunology including therapeutic discovery, immune profiling and personalized medicine. Its proprietary microengraving technology creates high-density bio-chip microarrays of the secreted products of single human cells derived from patient samples to provide analysis of antibody affinity and specificity, as well as cytokine profiles and T-cell functionality. The company was formerly known as Enumeral Technologies, Inc., and changed its name to Enumeral Biomedical Corp. in November 2010.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
YesPublic/Private
Publicly TradedStock Info
OTC : ENUMIP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2012 | 1 | NIH | $199,833 | |
Project Title: Igf::Ot::Igf Other Functions Enumeral Phase I, Topic 309, Detection Of Multiple Analytes From Small Tissue Samples |
Key People / Management
Arthur Tinkelenberg -- CEO
Barry Buckland -- Co-Founder
Christopher Love -- Co-Founder and Co-Chairman of The Scientific Advisory Board
Emanuele Ostuni -- Co-Founder and Director
Barry Buckland -- Co-Founder
Christopher Love -- Co-Founder and Co-Chairman of The Scientific Advisory Board
Emanuele Ostuni -- Co-Founder and Director